Published in Transpl Int on May 30, 2012
Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant (2016) 1.11
Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology (2011) 2.95
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl (2008) 1.61
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods (2010) 1.21
Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation (2011) 0.97
Zero risk tolerance costs lives: loss of transplantable organs due to human immunodeficiency virus nucleic acid testing of potential donors. Prog Transplant (2011) 0.81
Boceprevir for chronic HCV genotype 1 infection. N Engl J Med (2011) 0.79
The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl (2003) 0.79
Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology (1999) 0.78
Virologically compromised donor grafts in liver transplantation. J Hepatol (2004) 0.78
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol Depend (2004) 1.91
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl (2010) 1.70
Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology (Berl) (2005) 1.70
Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl (2004) 1.66
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl (2003) 1.61
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol (2011) 1.57
Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
Sirolimus--it doesn't deserve its bad Rap(a). J Hepatol (2011) 1.49
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40
High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. J Am Coll Cardiol (2003) 1.39
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2010) 1.35
Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl (2003) 1.31
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Indications for liver transplantation. Gastroenterology (2008) 1.28
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl (2008) 1.19
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl (2008) 1.18
Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl (2012) 1.18
Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant (2005) 1.17
Metastatic breast cancer presenting as acute liver failure. Gastroenterol Hepatol (N Y) (2011) 1.15
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score. Transpl Int (2006) 1.11
Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl (2007) 1.10
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Development of the allocation system for deceased donor liver transplantation. Clin Med Res (2005) 1.06
A survey of current liver biopsy practice patterns. J Clin Gastroenterol (2002) 1.03
Endoscopic gallbladder stent placement for treatment of symptomatic cholelithiasis in patients with end-stage liver disease. Am J Gastroenterol (2006) 1.01
Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl (2006) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl (2004) 0.96
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther (2006) 0.93
Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant (2004) 0.90
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl (2002) 0.90
The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) (2005) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2003) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl (2013) 0.87
Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl (2009) 0.87
Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int (2007) 0.86
Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int (2009) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl (2003) 0.85
Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl (2008) 0.85
A microplate assay specific for the enzyme aggrecanase. Anal Biochem (2003) 0.85
Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant (2013) 0.85
Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl (2014) 0.84
International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis (2009) 0.84
Hepatitis C screening: summary of recommendations from the clinical decision tool. Gastroenterology (2013) 0.83
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl (2013) 0.83
Tailoring antiviral therapy in hepatitis C. Hepatology (2006) 0.83
Arterioportal fistula requiring liver transplantation. Liver Transpl (2006) 0.82
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol (2003) 0.82
Sirolimus conversion for renal preservation in liver transplantation: not so fast. Liver Transpl (2008) 0.82
Immunosuppression and hepatocellular carcinoma. Liver Transpl (2011) 0.82
Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing abdominal and pelvic surgeries. Surg Endosc (2009) 0.82
Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl (2009) 0.82
Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant (2007) 0.82
Post-liver transplant survival in hepatitis C patients is improving over time. Liver Transpl (2009) 0.81
HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci (2010) 0.81
Endovascular caudal retraction of the cranial end of a misplaced Viatorr TIPS prior to liver transplantation. Proc (Bayl Univ Med Cent) (2012) 0.81
Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol (2008) 0.81
Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl (2003) 0.81
Living donor liver transplantation and hepatitis C. Clin Liver Dis (2003) 0.81
Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant (2007) 0.80
Expanding donor options: marginal, living, and split donors. Clin Liver Dis (2007) 0.80
Hepatocellular carcinoma extension into the right atrium. Liver Transpl (2003) 0.79
Spontaneous clearance of hepatitis C virus after liver transplantation. Transplantation (2009) 0.79
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation (2011) 0.79
Plasma levels of S100A4 in portopulmonary hypertension. Biomarkers (2009) 0.79
Torulopsis glabrata fungemia from infected transjugular intrahepatic portosystemic shunt stent. J Vasc Interv Radiol (2005) 0.78
Living donor liver transplantation in patients with hepatitis C. Liver Transpl (2003) 0.78
Baylor Regional Transplant Institute: an update on liver, kidney, and pancreas transplantation. Proc (Bayl Univ Med Cent) (2003) 0.78
Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother (2007) 0.78
Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl (2014) 0.78
The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension. Anesth Analg (2003) 0.78
Intraoperative imaging of pancreas transplant allografts using indocyanine green with laser fluorescence. Proc (Bayl Univ Med Cent) (2008) 0.78
Whole-organ pancreas transplantation at Baylor Regional Transplant Institute: a chance to cure diabetes. Proc (Bayl Univ Med Cent) (2010) 0.78